Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)

Who May Qualify: - Person willing to sign the study consent form - Person affiliated with a current social security scheme - Person with a definite diagnosis of Familial Hypercholesterolemia, defined by a Dutch Lipid Clinic Network (DLCN) clinical-biological score \> 8 and/or an identified causal mutation in the LDL receptor (LDLR) gene, apolipoprotein B100 gene, PCSK9 gene, or apolipoprotein E gene - Male aged 40 years or older, or female aged 50 years or older - Ability to understand French for questionnaire completion - Person not taking any lipid-lowering medication or on a stable dose of lipid-lowering therapy for at least one month prior to inclusion (three months for PCSK9 inhibitors) at Visit 1 - Person not taking any antihypertensive medication or on a stable dose of antihypertensive therapy for at least one month at Visit 1 - Person not taking any antidiabetic medication or on a stable dose of antidiabetic therapy for at least 3 months at Visit 1 Who Should NOT Join This Trial: - Subject with a technical contraindication for coronary CT scan: patient diameter \> 70 cm and/or weight \> 250 kg - Patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization) - Patient allergic to iodinated contrast agents - Severe renal insufficiency: estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula ≤ 30 ml/min - Subject with active cancer or in remission for less than 3 years - Subject who has received oral or intravenous corticosteroid therapy within the last 6 months - Subject with untreated or poorly controlled hypothyroidism - Subject receiving immunosuppressive or anticancer therapy - Subject refusing to participate - Subject under guardianship, curatorship, or judicial protection, or without social insurance coverage - Pregnant woman Always talk to your doctor about whether this trial is right for you.